文献速递垂体与肾上腺疾病性腺与生殖内分泌

氢化可的松颗粒治疗0-8岁先天性肾上腺皮质增生症及肾上腺功能不全患儿的前瞻性研究

A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究将17例CAH患儿和1例垂体功能减退患儿从药店配制胶囊转换为氢化可的松颗粒,前瞻性随访2年,CAH患儿每3个月依据唾液17-OHP谱调整治疗。结果显示精确给药与监测使氢化可的松剂量处于推荐范围低端、生长正常,且未发生肾上腺危象。

要点

  • 氢化可的松颗粒每日三次给药,唾液17-OHP谱可用于指导剂量调整
  • 研究结束时各年龄组氢化可的松剂量处于推荐范围低端
  • 随访期间未观察到肾上腺危象,生长无加速或减缓趋势

核心结论

  • 儿童肾上腺功能不全和CAH从出生起采用氢化可的松颗粒精确给药并结合唾液17-OHP监测,可获得推荐范围低端的剂量和正常生长,且未发生肾上腺危象。

研究设计与样本

  • 前瞻性研究,纳入17例CAH患儿(9例男性)和1例垂体功能减退男性患儿,年龄从出生至6岁,将氢化可的松由药店配制胶囊转换为氢化可的松颗粒,随访2年,共150次随访。

主要发现

  • 氢化可的松中位治疗持续时间(范围)为795(1-872)天,150次随访中有40次调整剂量,其中32次基于唾液测量、8次基于血清17-OHP水平。
  • 研究结束时2-8岁、1个月至2岁、<28天年龄组的中位每日氢化可的松剂量(范围)分别为10.2(7.0-14.4)、9.8(8.9-13.1)、8.6(8.2-13.7)mg/m2。
  • 生长无加速或减缓趋势;尽管记录到193例治疗中出现的不良事件(主要为常见儿童疾病),但未观察到肾上腺危象。

关键数值与推荐

  • 研究开始时2-8岁、1个月至2岁、<28天年龄组的中位每日氢化可的松剂量(范围)分别为11.9(7.2-15.5)、9.9(8.6-12.2)、12.0(11.1-29.5)mg/m2。
  • 研究结束时对应年龄组中位每日剂量(范围)分别为10.2(7.0-14.4)、9.8(8.9-13.1)、8.6(8.2-13.7)mg/m2。

临床怎么用

  • 对CAH和肾上腺功能不全患儿可使用氢化可的松颗粒实现精确给药,并利用唾液17-OHP谱每3个月指导剂量调整以维持推荐范围低端剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Children with congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI) require daily hydrocortisone replacement with accurate dosing. OBJECTIVE: Prospective study of efficacy and safety of hydrocortisone granules in children with AI and CAH monitored by 17-OHP (17-hydroxyprogesterone) saliva profiles. METHODS: Seventeen children with CAH (9 male) and 1 with hypopituitarism (male), aged from birth to 6 years, had their hydrocortisone medication changed from pharmacy compounded capsules to hydrocortisone granules. Patients were followed prospectively for 2 years. In children with CAH, the therapy was adjusted by 17-OHP salivary profiles every 3 months. The following parameters were recorded: hydrocortisone dose, height, weight, pubertal status, adverse events, and incidence of adrenal crisis. RESULTS: The study medication was given thrice daily, and the median duration of treatment (range) was 795 (1-872) days, with 150 follow-up visits. Hydrocortisone doses were changed on 40/150 visits, with 32 based on salivary measurements and 8 on serum 17-OHP levels. The median daily mg/m2 hydrocortisone dose (range) at study entry for the different age groups 2-8 years, 1 month to 2 years, <28 days was 11.9 (7.2-15.5), 9.9 (8.6-12.2), and 12.0 (11.1-29.5), respectively, and at end of the study was 10.2 (7.0-14.4), 9.8 (8.9-13.1), and 8.6 (8.2-13.7), respectively. There were no trends for accelerated or reduced growth. No adrenal crises were observed despite 193 treatment-emergent adverse events, which were mainly common childhood illnesses. INTERPRETATION: This first prospective study of glucocorticoid treatment in children with AI and CAH demonstrates that accurate dosing and monitoring from birth results in hydrocortisone doses at the lower end of the recommended dose range and normal growth, without occurrence of adrenal crises.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Neumann U, Braune K, Whitaker MJ, et al. A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules. J Clin Endocrinol Metab. 2021. PMID: 32888021. doi:10.1210/clinem/dgaa626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。